RPRX: Investor Sentiment and Bull/Bear Views
Royalty Pharma
Loading...
Loading...
Buzzberg insights
Attention & activity
- unique authors
- 0
- vs usual
- -100%
24h0
30d avg / day0
- unique authors
- 1
- vs usual
- New
7d1
4wk avg / week0
Author calls
What authors recommend
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
Author positions
What authors disclose
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
Feed & authors
- ideas
- 4
- Authors
- 3
- Sources
- 3
Call performance
Performance since each author’s call.
| Author | Direction | Return |
|---|---|---|
| Jim CramerJan 23 | Long | +70.0% |
Best calls over the past year · return since each call
Company facts
- Market cap
- $30.51B 2026-11-16
Financial results are not available yet.
Financial details
Market cap · polygon · 2026-11-16
Sentiment
Attention
0-100%vs usual
unique authors
30d avg / day 0
Attention
1Newvs usual
unique authors
4wk avg / week 0
Loading chart...
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
01:25
Jan 23
Jan 23
CNBC
YouTube
Loves Royalty Pharma's biotech funding model.
Cramer loves Royalty Pharma's business model of helping fund biotech and earning returns, says the stock just keeps going higher and calls it a terrific company.
01:01
Jan 23
Jan 23
CNBC
YouTube
Royalty Pharma's biopharma funding model works
Royalty Pharma keeps going higher; Cramer loves its step-function business model of funding biopharma and earning returns, and he has liked the company since its IPO.